Results 181 to 190 of about 106,090 (294)

Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: Long‐Term Follow‐Up of Deformations and Hemodynamics

Journal of Magnetic Resonance Imaging, EarlyView.
ABSTRACT Background A detailed evaluation of hemodynamics, supportive morphology, and deformation may help uncover the pathophysiology of hypertrophic obstructive cardiomyopathy (HOCM) and the changes wrought by alcohol septal ablation (ASA). Purpose To investigate the global cardiac volume, myocardial deformation, and hemodynamic characteristics ...
Kenichiro Suwa, Kazuto Ohno, Terumori Satoh, Ryota Sato, Keisuke Iguchi, Yuichiro Maekawa   +5 more
wiley   +1 more source

Disposition of emergency department patients presenting with angiotensin-converting enzyme inhibitor-induced angioedema. [PDF]

Int J Emerg Med
Briggs B, Cline D, Husain I.
europepmc   +1 more source

The First Occurrence of Angioedema After Discontinuation of Angiotensin-Converting Enzyme Inhibitor. [PDF]

Cureus, 2021
Kainat A, Phang CR, Ain NU, Agarwal B.
europepmc   +1 more source

Comparison of Angiotensin Converting Enzyme Inhibitors and Beta Blockers in Prevention of Atrial Fibrillation Recurrences After Electrical Cardioversion Elektriksel Kardiyoversiyon Sonrasında Atriyal

, 2007
ALTIN Timuçin GÜRLEK
openalex   +2 more sources

A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor. [PDF]

, 1989
Waterfall Jf
openalex   +1 more source

Olive‐derived bioactive combinations: synergistic angiotensin‐I‐converting enzyme (ACE) inhibition and distinct mechanisms of triterpenic acids and phenolics

Journal of the Science of Food and Agriculture, EarlyView.
Abstract BACKGROUND Cardiovascular diseases, largely driven by hypertension, remain the leading cause of mortality worldwide. Angiotensin‐I‐converting enzyme (ACE) inhibition is a well‐established therapeutic approach; however, synthetic inhibitors are frequently associated with adverse effects.
Fátima Rubio‐Senent, Alejandra Bermúdez‐Oria, África Fernández‐Prior, Antonio Lama‐Muñoz, Guillermo Rodríguez‐Gutiérrez, Juan Fernández‐Bolaños   +5 more
wiley   +1 more source

Angiotensin-Converting Enzyme Inhibitor-Drug Induced Liver Injury: Clinical Features and Diagnostic Features - A Systematic Review of Current Reported Cases. [PDF]

Korean J Gastroenterol
Suenghataiphorn T, Tribuddharat N, Danpanichkul P, Kulthamrongsri N.   +3 more
europepmc   +1 more source

Angiotensin-converting enzyme inhibitor promotes angiogenesis through Sp1/Sp3-mediated inhibition of notch signaling in male mice. [PDF]

Nat Commun, 2023
Lu H, Yuan P, Ma X, Jiang X, Liu S, Ma C, Philipsen S, Zhang Q, Yang J, Xu F, Zhang C, Zhang Y, Zhang W.   +12 more
europepmc   +1 more source

Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease

, 2019
Yao Qiao, Jung‐Im Shin, Yingying Sang, Lesley A. Inker, Alex Secora, Shengyuan Luo, Josef Coresh, G. Caleb Alexander, John W. Jackson, Alex R. Chang, Morgan E. Grams   +10 more
openalex   +2 more sources

Sacubitril/Valsartan Ameliorates Inflammation and Oxidative Stress in Hypertensive Heart Disease by Upregulating CAMKK2 Protein and Modulating the AMPK/AKT/GSK‐3β Axis

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Sacubitril/valsartan (Sac/Val) has emerged as an effective compound with myocardium‐protective functions in experimental and clinical trials for heart failure. This study investigated the function of Sac/Val in hypertensive heart disease (HHD) and explored the underlying mechanism.
Yan‐Jun Yang, Jiu‐Sheng Li
wiley   +1 more source